Upfront metastasis-directed therapy may be a viable treatment approach in patients with oligorecurrent disease, particularly those who wish to defer systemic therapy.
Men with GPS scores greater than 40 had a poor disease prognosis after surgery and their disease was likely to behave like that of high-risk patients.
A study suggested that the immunotherapy could be sensitizing non-Hodgkin lymphoma patients to subsequent therapies.
Enrichment of an early memory CD8+ T-cell phenotype in patients’ blood was predictive of their response to CAR-T therapy in CLL, NHL, and MM.
Efficacy limitations of CAR-T therapy in CLL may not be due to defects in the CAR-T product, but rather, to characteristics of the tumor cells.
High adherence to the at-home, stool-based screening test is a positive sign, but its impact on survival outcomes is still unclear.
A new study finds that blood-based measures of TMB correlate with response to pembrolizumab-based therapy in advanced lung cancer.
Two studies characterize hematological recovery after CAR-T cell therapy.
Axi-cel and tisa-cel are prescribed to distinct patient populations, possibly due to differing CAR-T manufacturing times, and differences in resource utilization.
Recent studies suggest that some misunderstanding around lead-time bias continues to persist in the literature.
